Corvus Pharmaceuticals In... (CRVS)
| Bid | 3.78 |
| Market Cap | 315.78M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -41.4M |
| EPS (ttm) | -1.03 |
| PE Ratio (ttm) | -3.98 |
| Forward PE | -5.78 |
| Analyst | Buy |
| Ask | 4.2 |
| Volume | 997,057 |
| Avg. Volume (20D) | 1,074,506 |
| Open | 4.31 |
| Previous Close | 4.34 |
| Day's Range | 3.91 - 4.31 |
| 52-Week Range | 1.75 - 10.00 |
| Beta | 0.57 |
About CRVS
undefined
Analyst Forecast
According to 0 analyst ratings, the average rating for CRVS stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts
1 month ago · seekingalpha.com
Corvus Pharmaceuticals, Inc. (CRVS) Q1 2025 Earnings Call TranscriptCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Zack Kubow - Real Chemistry, Investor Relations Leiv Lea - Chief Financial Offi...
2 months ago · seekingalpha.com
Corvus Pharmaceuticals' Short Runway Overshadows Soquelitinib's Promising TrialsCorvus Pharmaceuticals' leading drug candidate is Soquelitinib, which has broad potential across PTCL, atopic dermatitis, and ALPS. Unfortunately, it seems Corvus' early AD data might have disappointe...
3 months ago · seekingalpha.com
Corvus Pharmaceuticals, Inc. (CRVS) Q4 2024 Earnings Call TranscriptCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS ) Q4 2024 Earnings Conference Call March 25, 2025 4:30 PM ET Company Participants Zack Kubow - Real Chemistry, IR Leiv Lea - CFO Richard Miller - CEO Conferen...